Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to ...

SK Bioscience announced Wednesday that it has secured a definitive legal victory in its patent invalidation suit against Moderna, successfully challenging the biotech giant’s Korean patent related to ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

SEOUL, April 23 (Yonhap) -- SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has ...